Payload Information

General Information of This Payload
Payload ID
PAY0GKVJX
Name
Valeric-acid-calicheamicin
Synonyms
Valeric-acid-calicheamicin
   Click to Show/Hide
Target(s) Human Deoxyribonucleic acid (hDNA)
 Target Info 
Structure
Formula
C62H84IN3O24S3
Isosmiles
CCN(C(C)=O)C1COC(OC2C(OC3C#C/C=C\C#CC4(O)CC(=O)C(NC(=O)OC)=C3/C4=C\CSSC(C)(C)CCC(=O)O)OC(C)C(NOC3CC(O)C(SC(=O)c4c(C)c(I)c(OC5OC(C)C(O)C(OC)C5O)c(OC)c4OC)C(C)O3)C2O)CC1OC
InChI
InChI=1S/C62H84IN3O24S3/c1-14-66(33(6)67)35-28-83-41(26-39(35)78-9)88-54-49(73)46(30(3)85-59(54)87-38-19-17-15-16-18-22-62(77)27-37(69)47(64-60(76)82-13)44(38)34(62)21-24-91-93-61(7,8)23-20-40(70)71)65-90-42-25-36(68)56(32(5)84-42)92-57(75)43-29(2)45(63)52(55(81-12)51(43)79-10)89-58-50(74)53(80-11)48(72)31(4)86-58/h15-16,21,30-32,35-36,38-39,41-42,46,48-50,53-54,56,58-59,65,68,72-74,77H,14,20,23-28H2,1-13H3,(H,64,76)(H,70,71)/b16-15-,34-21+
InChIKey
GVOMFGFJEUWBHH-RUPRYQDQSA-N
Pharmaceutical Properties
Molecule Weight
1478.456
Polar area
354.02
Complexity
93
xlogp Value
3.82112
Heavy Count
93
Rot Bonds
25
Hbond acc
27
Hbond Donor
8
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Half Maximal Inhibitory Concentration (IC50) 112 pmol/L
HEK-293T cells
Normal
CVCL_0063 
[1]
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
SC-011 [Phase 1]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT03639194  Phase Status Phase 1
Clinical Description
A phase 1 study of ABBV-011 as a single-agent and in combination with budigalimab (ABBV-181) in subjects with relapsed or refractory small cell lung cancer.
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 22 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 15.30% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 LD(NAC-LD19.10)=0.24 mg/kg.
In Vivo Model SCLC PDX model (PDX: LU64)
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 35.60% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
In Vivo Model Small cell lung cancer PDX model (PDX: LU149)
Experiment 3 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 42.85% (Day 14) Negative SEZ6 expression (SEZ6-)
Method Description
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
In Vivo Model Small cell lung cancer PDX model (PDX: LU505)
Experiment 4 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 45.90% (Day 21) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 ADC=8mg/kg.
In Vivo Model SCLC PDX model (PDX: LU505)
Experiment 5 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 71.70% (Day 21) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 ADC=1 mg/kg.
In Vivo Model SCLC PDX model (PDX: LU149)
Experiment 6 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 87.00% (Day 21) Positive SEZ6 expression (SEZ6+++/++)
Method Description
NAC-LD19.10 ADC=8mg/kg.
In Vivo Model SCLC PDX model (PDX: LU505)
Experiment 7 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 89.80% (Day 29) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 ADC=1 mg/kg.
In Vivo Model SCLC PDX model (PDX: LU95)
Experiment 8 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 89.80% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
In Vivo Model Small cell lung cancer PDX model (PDX: LU149)
Experiment 9 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 92.00% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 ADC=0.5 mg/kg.
In Vivo Model SCLC PDX model (PDX: LU64)
Experiment 10 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 93.50% (Day 21) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 ADC=2 mg/kg.
In Vivo Model SCLC PDX model (PDX: LU149)
Experiment 11 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 94.78% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
In Vivo Model Small cell lung cancer PDX model (PDX: LU95)
Experiment 12 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 96.00% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
In Vivo Model Small cell lung cancer PDX model (PDX: LU64)
Experiment 13 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 96.80% (Day 29) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 ADC=2 mg/kg.
In Vivo Model SCLC PDX model (PDX: LU95)
Experiment 14 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 97.00% (Day 29) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 ADC=4 mg/kg.
In Vivo Model SCLC PDX model (PDX: LU95)
Experiment 15 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98.00% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 ADC=1 mg/kg.
In Vivo Model SCLC PDX model (PDX: LU64)
Experiment 16 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98.40% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 ADC=2 mg/kg.
In Vivo Model SCLC PDX model (PDX: LU64)
Experiment 17 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98.70% (Day 21) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 ADC=4 mg/kg.
In Vivo Model SCLC PDX model (PDX: LU149)
Experiment 18 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.60% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
In Vivo Model Small cell lung cancer PDX model (PDX: LU95)
Experiment 19 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.80% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
In Vivo Model Small cell lung cancer PDX model (PDX: LU95)
Experiment 20 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
In Vivo Model Small cell lung cancer PDX model (PDX: LU64)
Experiment 21 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
In Vivo Model Small cell lung cancer PDX model (PDX: LU64)
Experiment 22 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 28) Positive SEZ6 expression (SEZ6+++/++)
Method Description
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
In Vivo Model Small cell lung cancer PDX model (PDX: LU149)
References
Ref 1 ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors. Mol Cancer Ther. 2022 Jun 1;21(6):986-998.
Ref 2 A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer, NCT03639194
Ref 3 ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors. Mol Cancer Ther. 2022 Jun 1;21(6):986-998.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.